Literature DB >> 22748268

Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?

Vincent Grégoire1, Robert Jeraj, John Aldo Lee, Brian O'Sullivan.   

Abstract

Intensity-modulated radiation therapy (IMRT) is a conformal irradiation technique that enables steep dose gradients. In head and neck tumours this approach spares parotid-gland function without compromise to treatment efficacy. Anatomical and molecular imaging modalities may be used to tailor treatment by enabling proper selection and delineation of target volumes and organs at risk, which in turn lead to dose prescriptions that take into account the underlying tumour biology (eg, human papillomavirus status). Therefore, adaptations can be made throughout the course of radiotherapy, as required. Planned dose increases to parts of the target volumes may also be used to match the radiosensitivity of tumours (so-called dose-painting), assessed by molecular imaging. For swift implementation of tailored and adaptive IMRT, tools and procedures, such as accurate image acquisition and reconstruction, automatic segmentation of target volumes and organs at risk, non-rigid image and dose registration, and dose summation methods, need to be developed and properly validated.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748268      PMCID: PMC6225523          DOI: 10.1016/S1470-2045(12)70237-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  86 in total

1.  CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines.

Authors:  Vincent Grégoire; Peter Levendag; Kian K Ang; Jacques Bernier; Marijel Braaksma; Volker Budach; Cliff Chao; Emmanuel Coche; Jay S Cooper; Guy Cosnard; Avraham Eisbruch; Samy El-Sayed; Bahman Emami; Cai Grau; Marc Hamoir; Nancy Lee; Philippe Maingon; Karin Muller; Hervé Reychler
Journal:  Radiother Oncol       Date:  2003-12       Impact factor: 6.280

Review 2.  Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology.

Authors:  John A Lee
Journal:  Radiother Oncol       Date:  2010-08-11       Impact factor: 6.280

3.  Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.

Authors:  Piet Dirix; Vincent Vandecaveye; Frederik De Keyzer; Sigrid Stroobants; Robert Hermans; Sandra Nuyts
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

4.  Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort?

Authors:  Pierre Castadot; Xavier Geets; John Aldo Lee; Vincent Grégoire
Journal:  Radiother Oncol       Date:  2011-07-01       Impact factor: 6.280

5.  Survival analysis of head and neck squamous cell carcinoma: influence of smoking and drinking.

Authors:  Farzaneh Farshadpour; Hanneke Kranenborg; Eveline Van Beeck Calkoen; Gerrit Jan Hordijk; Ron Koole; Piet J Slootweg; Chris H Terhaard
Journal:  Head Neck       Date:  2010-08-24       Impact factor: 3.147

6.  Feasibility and sensitivity study of helical tomotherapy for dose painting plans.

Authors:  Michael A Deveau; Stephen R Bowen; David C Westerly; Robert Jeraj
Journal:  Acta Oncol       Date:  2010-10       Impact factor: 4.089

7.  Elective lymph node irradiation with intensity-modulated radiotherapy: is conventional dose fractionation necessary?

Authors:  Meena Bedi; Selim Firat; Vladimir A Semenenko; Christopher Schultz; Patrick Tripp; Roger Byhardt; Dian Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-01       Impact factor: 7.038

8.  A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density.

Authors:  S Webb; A E Nahum
Journal:  Phys Med Biol       Date:  1993-06       Impact factor: 3.609

9.  Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas.

Authors:  Jos M J A A Straetmans; Nadine Olthof; Jeroen J Mooren; Jos de Jong; Ernst-Jan M Speel; Bernd Kremer
Journal:  Laryngoscope       Date:  2009-10       Impact factor: 3.325

10.  The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.

Authors:  Zhixiong Lin; James Mechalakos; Sadek Nehmeh; Heiko Schoder; Nancy Lee; John Humm; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

View more
  31 in total

1.  Development of a software for quantitative evaluation radiotherapy target and organ-at-risk segmentation comparison.

Authors:  Jayashree Kalpathy-Cramer; Musaddiq Awan; Steven Bedrick; Coen R N Rasch; David I Rosenthal; Clifton D Fuller
Journal:  J Digit Imaging       Date:  2014-02       Impact factor: 4.056

Review 2.  Impact of weight loss in patients with head and neck carcinoma undergoing radiotherapy: is it an underestimated phenomenon? A radiation oncologist's perspective.

Authors:  J Cacicedo; A Dal Pra; F Alongi; A Navarro
Journal:  Eur J Clin Nutr       Date:  2015-04-29       Impact factor: 4.016

3.  Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Authors:  Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

Review 4.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

5.  Single high-dose vs. fractionated radiotherapy: Effects on plant growth rates.

Authors:  Marc Guedea; Antoni Castel; Marc Arnalte; Alex Mollera; Victor Muñoz; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-24

Review 6.  Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.

Authors:  Helen Cliffe; Chirag Patel; Robin Prestwich; Andrew Scarsbrook
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

7.  Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.

Authors:  Peter Lin; Myo Min; Mark Lee; Lois Holloway; Dion Forstner; Victoria Bray; Allan Fowler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-21       Impact factor: 9.236

Review 8.  Functional magnetic resonance imaging techniques and their development for radiation therapy planning and monitoring in the head and neck cancers.

Authors:  Jing Yuan; Gladys Lo; Ann D King
Journal:  Quant Imaging Med Surg       Date:  2016-08

9.  Comparison of swallowing function after intensity-modulated radiation therapy and conventional radiotherapy for head and neck cancer.

Authors:  Barbara Roa Pauloski; Alfred W Rademaker; Jerilyn A Logemann; Muveddet Discekici-Harris; Bharat B Mittal
Journal:  Head Neck       Date:  2014-08-01       Impact factor: 3.147

Review 10.  Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective.

Authors:  Katsumasa Nakamura; Tomonari Sasaki; Saiji Ohga; Tadamasa Yoshitake; Kotaro Terashima; Kaori Asai; Keiji Matsumoto; Yoshiyuki Shioyama; Hiroshi Honda
Journal:  Int J Clin Oncol       Date:  2014-07-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.